Peptide Profile

Tesamorelin

GHRH Analog for Visceral Fat Reduction

Overview

Composition

Synthetic analog of human growth hormone-releasing hormone (GHRH), comprising 44 amino acids with modifications to enhance stability and half-life

Mechanism of Action

Binds to GHRH receptors in the anterior pituitary to stimulate endogenous growth hormone (GH) release, which then promotes lipolysis (fat breakdown) particularly in visceral adipose tissue through GH/IGF-1 axis activation

Primary Effects

Demonstrated reductions in excess visceral abdominal fat in HIV-associated lipodystrophy, with other metabolic uses remaining exploratory.

Discovery & Background

Developed by Theratechnologies in the early 2000s specifically to address lipodystrophy and excess visceral fat in HIV-infected patients on antiretroviral therapy (ART)

FDA approval in November 2010 as Egrifta® for reduction of excess abdominal fat in HIV-associated lipodystrophy. Subsequent research expanded into metabolic syndrome, NAFLD, and general obesity applications

FDA-approved for HIV-associated lipodystrophy; other metabolic or body-composition uses remain off-label or investigational

Research Overview

Pivotal Phase 3 trials in HIV lipodystrophy demonstrated visceral fat reductions, while metabolic effects vary by endpoint

01
Reduced visceral adipose tissue (VAT) by ~15-18% over 26 weeks in HIV patients
02
Improved lipid profiles (triglycerides, HDL cholesterol)
03
Enhanced insulin sensitivity and glucose metabolism markers
04
Sustained benefits with continued use; effects reverse upon discontinuation
05
IGF-1 elevations require interpretation because the drug acts through the GH/IGF-1 axis
06
Evidence outside the HIV-lipodystrophy indication is much less mature
07
Exploratory studies have evaluated non-HIV visceral obesity, NAFLD/NASH, and metabolic syndrome
08
Cardiovascular risk-marker changes should be interpreted through the approved visceral-fat indication and trial endpoints

FDA-approved for HIV-associated lipodystrophy; other indications (general visceral obesity, NAFLD) remain off-label or investigational

Safety Considerations

Monitoring

Visceral adipose tissue (VAT) via imaging (CT/MRI)
Lipid panel (triglycerides, HDL, LDL)
Fasting glucose and HbA1c
IGF-1 levels
Liver function tests (if using for NAFLD)
Body composition measurements

Side Effects

Common (Mild)

Local redness, itching, or discomfort can occur
Peripheral edema (fluid retention)
Arthralgia (joint pain)
Myalgia (muscle pain)
Carpal tunnel symptoms (related to GH effects)

Metabolic

Transient increases in blood glucose (monitor in diabetics)
Potential insulin resistance with prolonged GH elevation (rare)

Rare but Serious

Hypersensitivity reactions
Concerns about potential tumor growth (GH can promote proliferation—avoid in active cancer)

Contraindications

Active malignancy or history of cancer (especially pituitary tumors)
Diabetic retinopathy or proliferative conditions
Critical illness (acute catabolic states)
Hypersensitivity to tesamorelin or components
Pregnancy or breastfeeding (insufficient safety data)

Educational Notice

Tesamorelin (Egrifta®) is FDA-approved specifically for reduction of excess abdominal visceral fat in HIV-associated lipodystrophy, supported by pivotal Phase 3 trials. Use for general visceral obesity, metabolic syndrome, NAFLD, or aging-related body-composition claims is not FDA-approved and lacks the same level of clinical validation. Benefits are sustained only with continued use and reverse upon discontinuation. Compounded formulations may vary in quality, and clinical decisions require qualified medical oversight.

References